23 Feb MEDIPOST America
Antonio Lee, Ph.D., CEO and Managing Director
Oct. 13 | 11:00am | BlueRock Therapeutics Ballroom
MEDIPOST America is a wholly-owned subsidiary of MEDIPOST headquartered in Seoul, Korea. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human umbilical cord blood-derived mesenchymal stromal cells with clinical-stage assets in the disease areas of osteoarthritis, broncho-pulmonary dysplasia, and Alzheimer’s disease. MEDIPOST’s preclinical-stage pipeline includes Acute Respiratory Distress Syndrome, alopecia, and diabetic nephropathy. CARTISTEM® was approved in 2012 in Korea with the label “treatment of knee articular cartilage defects in patients with OA as a result of degenerative disease or repeated trauma”. To date, over 18,000 patients have been treated on the market with an excellent long-term safety and efficacy profile. PNEUMOSTEM® for the prevention of Bronchopulmonary Dysplasia in premature infants demonstrated significant benefit in survival and cognitive development compared to premature infants who received standard care alone.